Initial spontaneous clearance and re-infection with a distinct hepatitis C virus genotype leading to chronic hepatitis C in an HIV+ intravenous drug user [3]

AIDS

Volumn 22, Issue 2, 2008, Pages 318-

  Vispo, Eugenia ^a   Martinez Alarcon, José ^a   Poveda, Eva ^a   Toro, Carlos ^a   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; LIVER ENZYME; VIRUS RNA;

CD4 LYMPHOCYTE COUNT; DISEASE COURSE; GENE DELETION; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HETEROZYGOSITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNITY; INTRAVENOUS DRUG ABUSE; LETTER; PRIORITY JOURNAL; REINFECTION; SEXUAL BEHAVIOR; VIREMIA;

ADULT; GENETIC PREDISPOSITION TO DISEASE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HETEROZYGOTE; HIV; HIV SEROPOSITIVITY; HUMANS; MALE; RECEPTORS, CCR5; RISK FACTORS; SEXUAL BEHAVIOR; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 37549023797     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3282f36f46     Document Type: Letter

References (9)

1. Stewart G, Ashton L, Biti R, French R, Bennetts B, Newcombe N, et al. Increased frequency of CCR5 delta 32 heterozygotes among long-term nonprogressors with HIV-1 infection. AIDS 1997; 11:1833-1838.
2. Goulding C, McManus R, Murphy A, McDonald G, Barrett S, Crowe J, et al. The CCR5-delta32 mutation: impact on disease outcome in individuals with hepatitis C infection from a single source. Gut 2005; 54:1508-1515.
3. Fellay J, Shianna K, Ge D, Colombo S, Ledergerber B, Weale M, et al. A whole genome association study of major determinants for host control of HIV-1. Science 2007; 317:944-947.
4. Houghton M, Abrignani S. Prospects for a vaccine against the hepatitis C virus. Nature 2005; 436:961-966.
5. McMahon J, Pouget E, Tortu S. Individual and couple-level risk factors for hepatitis C infection among heterosexual drug users: a multilevel dyadic analysis. J Infect Dis 2007; 195:1572-1581.
6. Soriano V, Mocroft A, Ledergerber B, Knysz B, Chaplinskas S, Peters L, et al. Epidemiological and virological characteristics of chronic hepatitis C virus infection within the EuroSIDA observational cohort. Abstract of the 11th European AIDS Conference; 24-27 October 2007. Madrid, Spain; 2007.
7. Mehta S, Cox A, Hoover D, Wang X, Mao Q, Ray S, et al. Protection against persistence of hepatitis C. Lancet 2002; 359:1478-1483.
8. Grebely J, Raffa J, Lai C, Krajden M, Conway B, Tyndall M. Factors associated with spontaneous clearance of hepatitis C virus among illicit drug users. Can Gastroenterol 2007; 21:447-451.
9. Garfein R, Vlahov D, Galai N, Doherty M, Nelson K. Viral infections in short-term injection drug users: the prevalence of hepatitis C, hepatitis B, human immunodeficiency and human T-lymphotropic viruses. Am J Pub Health 1996; 86:655-661.